SEARCH RESULT

Total Matching Records found : 7462

A healthier India: Need to resolve conflict between drug price controls, innovation and affordable healthcare-David Taylor

The debate about essential-medicine pricing and access in India illustrates the difficulties inherent in establishing policies that serve conflicting public interests in achieving goals such as caring well and ensuring safety for all, while also pursuing financially-sustainable success in scientific innovation and trade. It highlights problems facing those interested in continuing drug and vaccines development and ensuring that, once marketed, such products contribute effectively to improving public health. Modern pharmaceuticals...

More »

SIT rejects amicus curiae's observations against Modi-Manas Dasgupta

It dismisses as “false and fabricated documents” fax messages claimed to have been sent by Sanjiv Bhatt The Supreme Court-appointed Special Investigation Team has totally disagreed with the observations of amicus curiae Raju Ramachandran, and said no case can be made out against Gujarat Chief Minister Narendra Modi in connection with the 2002 communal riots under any of the Sections of the Indian Penal Code mentioned by him. Mr. Ramachandran, in his...

More »

Gujarat riots: 'So what if words were spoken within 4 walls?'

-Express News Service The Supreme Court appointed Special Investigation Team (SIT) has concluded that even if Narendra Modi gave an illegal verbal instruction to allow Hindus to “vent their anger” after the Godhra carnage, it was not an offence. “...The interpretations made on alleged illegal instructions given by the Chief Minister by (police officers) Shri R B Sreekumar and Shri Sanjiv Bhatt, appear to be without any basis. Further, even if such...

More »

Bayer to challenge Cipla’s decision to cut price of cancer drug

-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...

More »

New, improved NREGA 2.0

-The Deccan Chronicle Seven years after unveiling the rural job guarantee scheme, the Centre on Tuesday announced a major extension of scope of works under the Mahatma Gandhi National Rural Employment Guarantee Act (MNREGA) in a bid to revive demand for jobs, which witnessed over 20 per cent dip in the last financial year. Union rural development minister Jairam Ramesh on Tuesday tabled the “MNREGA 2.0 — the second generation reforms”...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close